Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Table 2 General protease inhibitor description with computed tomography results since 2011
| PI | Genotype | PI treatment duration (wk) | Treatment duration (wk) | Treatment regimen | PEG-IFNα | Publication date |
| Telaprevir | 1а/1b/1с/unknown | 12/8 | 20/24/44/48 | 750 mg TID | (+) | 2011 |
| Boceprevir | 1а/1b/unknown | 24/32/44 | 28/36/48 | 800 mg TID | (+) | 2011 |
| Daclatasvir | 1а/1b | 24 | 24 | 60 mg/d | (+/-) | 2012 |
| Asunaprevir | 1а/1b | 24 | 24 | 600 mg BID | (+/-) | 2012 |
| АВТ-450 | 1а/1b | 12 | 12 | 250/150 mg/d | (-) | 2013 |
- Citation: Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J Hepatol 2014; 6(5): 326-339
- URL: https://www.wjgnet.com/1948-5182/full/v6/i5/326.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i5.326